Stoke Therapeutics Inc

Insider sales at Stoke Therapeutics show routine plan‑driven trading as its Dravet candidate advances Phase III, while share price lingers near a 52‑week low.

Stoke Therapeutics insider trades reveal cautious liquidity strategy amid promising phase‑III results for zorevunersen and potential Biogen partnership.

Stoke Therapeutics insider buys reveal confidence in its ASO platform for SMA, Fast‑Track status, and promising early efficacy—what investors need to know.